Cracking the code to the MYC oncogene
Sunrise or sunset for therapeutics against an intractable oncogene?
In our perpetual search for cool and interesting new developments coming through in cancer research we stumbled upon an unexpected surprise.
The good news is it’s aimed at an intractable target where there is a high unmet medical need across a range of different cancers and recently entered clinical evaluation.
The bad news is the outcome is uncertain (as yet), plus there are some key challenges we have identified.
Somewhere in between lies the truth of the matter, although there are a few clues where we can put some stakes in the ground as reference points to come back to.
In our latest assessment, we take a look at what is known as well as some of the potential unknown unknowns, and how they might impact the eventual outcome.
We weren’t as excited as many were at ENA22 with an entirely different approach, yet this one piqued our interest and may have more promise…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
